Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Pier Capital LLC

Pier Capital LLC trimmed its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 132,604 shares of the company’s stock after selling 1,687 shares during the quarter. Pier Capital LLC owned 0.23% of Structure Therapeutics worth $3,596,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of GPCR. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Structure Therapeutics in the fourth quarter valued at $40,000. Assetmark Inc. lifted its position in shares of Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock valued at $62,000 after acquiring an additional 953 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in shares of Structure Therapeutics by 29.8% during the 4th quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock worth $115,000 after acquiring an additional 971 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

GPCR stock opened at $21.05 on Tuesday. The stock has a market cap of $1.21 billion, a P/E ratio of -28.45 and a beta of -2.37. The firm has a 50 day simple moving average of $24.71 and a 200 day simple moving average of $31.63. Structure Therapeutics Inc. has a 52 week low of $19.39 and a 52 week high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Sell-side analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on GPCR shares. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. William Blair began coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. Finally, JMP Securities restated a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.